Immune checkpoint inhibitors induced liver injury: an observational study

Results: 851 subjects (513 received CoronaVac and 338 received Comirnaty; 56.2% male, median age 52 years old; 6.8% chronic hepatitis B or C) were included.Majority (87%) subjects had normal ALT (1-2 × ULN: 10.8/%; >2 × ULN: 2.4%), total bilirubin (1-2 × ULN: 3.3%; >2 × ULN: 0%) and ALP (1-2 × ULN: 5.4%; >2 × ULN: 0.5%) before or at the time of receiving COVID-19 vaccines; these parameters remained stable for up to 3 months after the vaccination-ALT (1-2 × ULN: 11.6%; >2 × ULN: 2.1%), total bilirubin (1-2 × ULN: 3.7%; >2 × ULN: 0%) and ALP (1-2 × ULN: 5.4%; >2 × ULN: 0.8%) at or after the time of receiving COVID-19 vaccines.While patients with chronic viral hepatitis had higher ALT and ALP than those without chronic viral hepatitis at most of the times, these parameters remained normal (ALT: median 24 to 26 U/L vs. 20 to 21 U/L; ALP: median 88 to 90 U/L vs. 80 U/L).Similar serial liver biochemistries were observed in subjects who received CoronaVac and Comirnaty vaccine.Conclusion: Both types of COVID-19 vaccines have very favourable liver safety profile in people with or without chronic viral hepatitis.